Celldex to Participate in Upcoming Investor Conferences
November 11, 2021 07:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor...
Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 09, 2021 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2021 and provided a corporate...
Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021
September 29, 2021 00:00 ET
|
Celldex Therapeutics, Inc.
- Rapid and sustained improvement in urticaria control after single dose of CDX-0159 -- Greatly improved patient quality of life and reduced disease impact -- Data further support 95% complete...
Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 24, 2021 07:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual...
Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress
September 23, 2021 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase...
Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study
September 13, 2021 09:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation...
Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021 16:01 ET
|
Celldex Therapeutics, Inc.
- Positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021 - - Raised $287 million in gross proceeds from a follow-on public offering of common stock, closed...
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 16, 2021 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., July 16, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public...
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock
July 13, 2021 20:30 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381...
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
July 12, 2021 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market...